Sermorelin Acetate vs Tesamorelin

Sermorelin Acetate

Sermorelin acetate is a synthetic 29-amino acid peptide corresponding to the first 29 residues of the 44-amino acid human growth hormone-releasing hormone (GHRH 1-29). It represents the shortest fully functional fragment of GHRH capable of activating the GHRH receptor on anterior pituitary somatotrophs. Sermorelin was FDA-approved (marketed as Geref) for diagnostic evaluation of pituitary GH secretory capacity and was previously used in pediatric growth hormone deficiency research. Its mechanism involves GHRH-R binding, which activates adenylyl cyclase-cAMP-PKA signaling to stimulate GH gene transcription, synthesis, and pulsatile release. Clinical studies by Vittone et al. (Journal of Clinical Endocrinology and Metabolism, 1997) demonstrated that sermorelin administration in elderly subjects increased GH secretion and improved body composition markers including lean body mass and skin thickness. Importantly, because sermorelin works through the native GHRH receptor, GH release remains subject to somatostatin-mediated negative feedback, preserving physiological regulation unlike direct GH administration. Research has also explored sermorelin in cardiovascular contexts, where GH-IGF-1 axis activation may support cardiac tissue remodeling, and in seizure models where GHRH receptor activation appears to have neuroprotective effects. Compared to CJC-1295 (with or without DAC), sermorelin has a shorter half-life of approximately 10-20 minutes, requiring more frequent administration but producing very precise, physiological GH pulses. Store lyophilized powder at -20C; reconstitute with bacteriostatic water and refrigerate at 2-8C for up to 14 days. Sermorelin is studied by pediatric endocrinology research centers, geriatric medicine departments, and cardiovascular research institutions investigating GH axis modulation.

Tesamorelin

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) consisting of the 44-amino acid human GHRH sequence with a trans-3-hexenoic acid modification at the N-terminus. It acts by binding to GHRH receptors on anterior pituitary somatotroph cells, stimulating pulsatile growth hormone (GH) release while preserving the natural hypothalamic-pituitary feedback axis. Tesamorelin received FDA approval (marketed as Egrifta) for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, based on pivotal trials demonstrating approximately 15-18% reduction in visceral adipose tissue over 26 weeks (Falutz et al., JAMA 2007). Beyond lipodystrophy research, studies published in Annals of Neurology (Baker et al., 2012) suggest tesamorelin may improve cognitive function in older adults with mild cognitive impairment by modulating IGF-1 levels in the central nervous system. Compared to direct GH administration, tesamorelin preserves physiological GH pulsatility rather than creating supraphysiological sustained GH levels, which research indicates may reduce the risk of insulin resistance associated with exogenous GH. Additional preclinical work has explored its role in peripheral nerve regeneration models. The lyophilized powder should be stored at controlled room temperature (20-25C) or refrigerated; reconstitute with sterile water and use within 24 hours or refrigerate for up to 14 days. This peptide is studied by endocrinology research labs, HIV metabolism centers, and neuroscience institutions investigating GH-IGF-1 axis modulation.

Frequently Asked Questions